Joris Winderickx
Corporate Officer/Principal en reMYND NV .
Cargos activos de Joris Winderickx
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
reMYND NV
 reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Corporate Officer/Principal | 30/05/2012 | - |
| Director/Miembro de la Junta | 01/01/2002 | 30/05/2012 | |
| Fundador | 09/11/2009 | - |
Historial de carrera de Joris Winderickx
Antiguos cargos conocidos de Joris Winderickx.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| Royal Flemish Chemical Society | Fundador | - | - |
ADx NeuroSciences NV
 ADx NeuroSciences NV BiotechnologyHealth Technology ADx NeuroSciences NV develops proprietary state-of-the-art biomarker-assays diagnosing a wide variety of neurodegenerative diseases and conditions. The ADx tests provide unique access to early detection of Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The company was founded in 2011 by Paul Appermont, Koen Dewaele, Hugo Vanderstichele and Eugeen Vanmechelen and is headquartered in Ghent, Belgium. | Director/Miembro de la Junta | - | - |
| Katholieke Universiteit Leuven | Corporate Officer/Principal | - | - |
Formación de Joris Winderickx.
| Katholieke Universiteit Leuven | Doctorate Degree |
Estadísticas
Internacional
| Bélgica | 5 |
Operativa
| Director/Board Member | 2 |
| Founder | 2 |
| Corporate Officer/Principal | 2 |
Sectorial
| Commercial Services | 2 |
| Consumer Services | 2 |
| Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 3 |
|---|---|
reMYND NV
reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Commercial Services |
| Royal Flemish Chemical Society | |
ADx NeuroSciences NV
ADx NeuroSciences NV BiotechnologyHealth Technology ADx NeuroSciences NV develops proprietary state-of-the-art biomarker-assays diagnosing a wide variety of neurodegenerative diseases and conditions. The ADx tests provide unique access to early detection of Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The company was founded in 2011 by Paul Appermont, Koen Dewaele, Hugo Vanderstichele and Eugeen Vanmechelen and is headquartered in Ghent, Belgium. | Health Technology |
- Bolsa de valores
- Insiders
- Joris Winderickx
- Experiencia
